![Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis - Digestive and Liver Disease Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis - Digestive and Liver Disease](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/2d8ce941-c21d-47d2-bfdc-8ad0f0503aac/gr1.jpg)
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis - Digestive and Liver Disease
MIRRI - Microbial Resource Research Infrastructure - Several MIRRI members attended the 38th Congress of the European Culture Collections' Organisation (ECCO) held in Moscow from 13 to 15 September 2018. Serge Casaregola,
![Review of the 17th Congress of the European Crohn's and Colitis Organisation (ECCO) - European Medical Journal Review of the 17th Congress of the European Crohn's and Colitis Organisation (ECCO) - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2022/03/Feature-Image-Gastroenterology-11-Supplement-1-ECCO-940x563.jpg)
Review of the 17th Congress of the European Crohn's and Colitis Organisation (ECCO) - European Medical Journal
![European Crohn´s and Colitis Organisation - ECCO - Paediatric news from the 13th Congress of ECCO 2018 European Crohn´s and Colitis Organisation - ECCO - Paediatric news from the 13th Congress of ECCO 2018](https://www.ecco-ibd.eu/images/6_Publication/6_2_ECCO_News/ECCO_News_Images/Issue1_2018/11_01_Thursday-202.jpg)